Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2003

View Archived Issues

Rivastigmine reduces decline in daily activities in moderately severe AD

Prasterone prevents bone mineral loss in women with SLE

Hyperalgesic and analgesic effects of F-13640 following chronic dosing

Non-TZD PPAR modulator with potentially improved biological responses

Novel antimalarial artemisin derivatives claimed by Chinese research team

New CCR3 antagonists in early development at Bayer

Novel antiallergic agents discovered by Sumitomo researchers

Kaken presents new androgen receptor modulators

New erythromycin antibiotics prepared and tested by Hokuriku Seiyaku researchers

Novel 17beta-HSD type 3 inhibitors and their use in cancer and prostate disorders

Allergen-induced airway inflammation reduced by a caspase inhibitor in a murine model of asthma

Antipsychotic efficacy of a 5-HT2/dopamine D2 receptor antagonist shown in a murine model

FTC clears Pfizer's acquisition of Pharmacia

Elite develops opioid antagonist product to minimize abuse potential

GenVec and Diacrin to merge

Dyax and Alnis collaborate on therapeutic peptides for cancer

Certican demonstrates superiority to azathioprine in lung transplant patients

Patient enrollment completed in phase IIa trial of Onyvax-P

Canvaxin partial hold lifted, phase III enrollment to resume

Revimid granted fast track status for myelodysplastic syndromes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...